Skip to content

Clinical Evaluation of Detection of High Risk HPV in Urine

Clinical Evaluation Study of Urine hrHPV Detection for the Diagnosis of Presence of Cervical HPV and Correlation of Cervical Lesions

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05210348
Acronym
Urine-hrHPV
Enrollment
1000
Registered
2022-01-27
Start date
2021-09-15
Completion date
2022-05-01
Last updated
2022-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenocarcinoma in Situ, Atypical Glandular Cells, Atypical Glandular Cells, Favor Neoplastic, Atypical Glandular Cells Not Otherwise Specified, Atypical Squamous Cells, Cannot Rule Out High-grade Squamous Intraepithelial Lesion, Atypical Squamous Cells of Undetermined Significance, Cervical Adenocarcinoma, Cervical Cancer, Cervical Intraepithelial Neoplasia Grade I, Cervical Intraepithelial Neoplasia Grade II, Cervical Intraepithelial Neoplasia, Grade III, Cervical Squamous Cell Carcinoma, Cervical Squamous Intraepithelial Lesion, High-Grade Squamous Intraepithelial Lesions, Human Papilloma Virus, Human Papillomavirus Infection, Low-grade Squamous Intraepithelial Lesion, Negative for Intraepithelial Lesion or Malignancy

Keywords

Urine testing for high-risk HPV, Human papilloma virus, Cervical cancer

Brief summary

Cervical cancer is one of the most common tumors in women, which seriously threatens women's life quality and safety. Human papilloma virus (HPV) infection is the most common cause of cervical cancer. Traditional HPV testing is based on the cells sample shed from the cervix. Recent studies have shown that urine HPV detection can be used as a new HPV detection method. This study intends to include patients undergoing TCT /HPV test/colposcopy in the department of gynecological diseases of the hospital, and collect urine samples and cervical swab samples. Sanger sequencing and cervical swab HPV test results were compared to evaluate the accuracy and clinical validity of urine HPV test combined with clinical diagnosis results of cases.

Detailed description

The urine high-risk HPV detection reagent (PCR-fluorescent probe method) developed by Hangzhou Newhorizon Health Technology Co., Ltd. can qualitatively detect 14 high-risk HPV DNA in human urine samples, including HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and can detect HPV 16 and 18. This test adopts the comparative clinical research method, by collecting urine samples and cervical swab samples from the same subject for HPV nucleic acid detection. Among them, urine samples were tested for high-risk HPV nucleic acid testing and Sanger sequencing, and cervical swab samples were tested with HPV testing kits for cervical swabs that have been on the market. Combined with the clinical diagnosis results of the cases, the performance of the urine HPV detection technology is compared and evaluated. For patients undergoing TCT testing/HPV testing/colposcopy in the gynecological clinic or colposcopy clinic of the hospital, the subjects will be screened through the admission criteria and signed an informed consent; the examiner is required to collect cervical swab samples and, at the same time, issue urine collection When the tube is given to the subject, the subject must collect urine samples by themselves according to the sampling instructions or under the guidance of medical personnel; the patient samples will be tested by Hangzhou Newhorizon Health Technology Co., Ltd.; the clinical examination report will be collected as the case materials of this study.

Interventions

None listed

Sponsors

Hangzhou Mingze Medical Research Co., Ltd.
CollaboratorUNKNOWN
Beijing Tsingke Biological Technology Co., Ltd. Hangzhou Branch
CollaboratorUNKNOWN
Hangzhou Newhorizon Health Technology Co., Ltd.
CollaboratorUNKNOWN
Peking University People's Hospital
Lead SponsorOTHER

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

1. Women aged 20-65 years old; 2. Have a history of sexual life; 3. The patients were voluntarily enrolled in the group and signed an informed consent form.

Exclusion criteria

1. History of cervical conization, pelvic radiation and hysterectomy, acute inflammation of the reproductive tract, severe system disease or other malignant tumors; 2. Pregnant and lactating women; 3. The patient's compliance is poor or the researcher thinks it is not suitable for this study.

Design outcomes

Primary

MeasureTime frameDescription
Verification of accuracy2022/5Consistency analysis of urine HPV test and Sanger sequencing results/cervical swab HPV test results The main evaluation indicators are the total test positive coincidence rate, total test negative coincidence rate, total coincidence rate, 16/18/other 12 types of positive and negative coincidence rates, kappa value and 95% confidence interval.

Secondary

MeasureTime frameDescription
Clinical validity verification2022/5Using the clinical diagnosis result (colposcopy or pathology report) of the case as the gold standard, evaluate the sensitivity, specificity and the corresponding 95% confidence interval, etc. of the HPV detection of urine samples and cervical swab samples for cervical intraepithelial neoplasia grade II and above (≥CIN2)

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026